Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$26.12 - $34.07 $18.4 Million - $24 Million
-704,910 Reduced 81.31%
161,988 $5.52 Million
Q1 2024

May 15, 2024

BUY
$26.64 - $40.31 $20.3 Million - $30.8 Million
763,361 Added 737.28%
866,898 $30.5 Million
Q4 2023

Feb 14, 2024

SELL
$19.95 - $31.0 $8.34 Million - $13 Million
-417,808 Reduced 80.14%
103,537 $2.99 Million
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $11.1 Million - $31 Million
521,345 New
521,345 $11.9 Million
Q1 2023

May 15, 2023

SELL
$26.01 - $48.69 $5.72 Million - $10.7 Million
-219,835 Reduced 55.53%
176,075 $6.63 Million
Q4 2022

Feb 14, 2023

SELL
$24.14 - $30.37 $178,467 - $224,525
-7,393 Reduced 1.83%
395,910 $10.6 Million
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $8 Million - $12 Million
360,012 Added 831.61%
403,303 $11.4 Million
Q2 2022

Aug 15, 2022

SELL
$19.74 - $43.01 $939,860 - $2.05 Million
-47,612 Reduced 52.38%
43,291 $939,000
Q1 2022

May 16, 2022

BUY
$36.25 - $52.02 $1.62 Million - $2.32 Million
44,610 Added 96.36%
90,903 $3.65 Million
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $1.05 Million - $1.32 Million
19,502 Added 72.79%
46,293 $2.62 Million
Q1 2021

May 17, 2021

SELL
$29.77 - $84.85 $1.7 Million - $4.83 Million
-56,949 Reduced 68.01%
26,791 $1.7 Million
Q4 2020

Feb 16, 2021

BUY
$25.66 - $34.55 $743,934 - $1 Million
28,992 Added 52.96%
83,740 $2.81 Million
Q3 2020

Nov 16, 2020

BUY
$22.51 - $30.11 $158,560 - $212,094
7,044 Added 14.77%
54,748 $1.5 Million
Q2 2020

Aug 14, 2020

SELL
$12.65 - $29.57 $26,425 - $61,771
-2,089 Reduced 4.2%
47,704 $1.29 Million
Q1 2020

May 15, 2020

SELL
$10.84 - $20.85 $342,836 - $659,422
-31,627 Reduced 38.84%
49,793 $731,000
Q2 2019

Aug 14, 2019

BUY
$18.0 - $19.82 $1.47 Million - $1.61 Million
81,420 New
81,420 $1.61 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.